Tumor necrosis factor (cachectin) in human visceral leishmaniasis

Journal of Infectious Diseases

Volumn 163, Issue 4, 1991, Pages 853-857

  Barral Netto, M ^a   Badaro R ^b   Barral, A ^b   Almeida, R P ^b   Santos, S B ^b   Badaro F ^b   Pedral Sampaio, D ^b   Carvalho, E M ^b   Falcoff, E ^b   Falcoff, R ^b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MEGLUMINE ANTIMONATE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; FEMALE; HUMAN; IMMUNE RESPONSE; LEISHMANIA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SERUM; VISCERAL LEISHMANIASIS;

ACUTE DISEASE; ANTIMONY; ANTIPROTOZOAL AGENTS; CELLS, CULTURED; COMBINED MODALITY THERAPY; FEMALE; HUMAN; INTERFERON-GAMMA, RECOMBINANT; LEISHMANIASIS, VISCERAL; MACROPHAGES; MALE; MEGLUMINE; ORGANOMETALLIC COMPOUNDS; SUPPORT, NON-U.S. GOV'T; TUMOR NECROSIS FACTOR;

EID: 0025891596     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/163.4.853     Document Type: Article

References (41)

1. Andrade TM, Teixeira R, Andrade JAF, Pereira C, Carvalho EM. Estudo da hipersensibilidade de tipo retardado na leishmaniose visceral. Rev Inst Med Trop Sao Paulo 1982;24:298-302.
2. Carvalho EM, Bacellar O. Lymphocyte reactivity to mitogens in American visceral leishmaniasis. Braz J Med Biol Res 1983;16:35-41.
3. Cerf BJ, Jones TC, Badaro R, Sampaio D, Teixeira R, Johnson WD Jr. Malnutrition as a risk factor for severe visceral leishmaniasis in northern Brazil. J Infect Dis 1987;156:1030-3.
4. Beutler B, Greco AV, Caputo S, Caradonna P, Grieco A, Laghi V. Visceral leishmaniasis presenting with hypertrigliceridemia. Lancet 1982; 2:504-5.
5. Barral A, Carvalho EM, Badaro R, Barral-Netto M. Suppression of lymphocyte proliferative responses by sera from patients with American visceral leishmaniasis. Am J Trop Med Hyg 1986;35:735-42.
6. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 1988;240:1546-8.
7. Rampart M, De Smet W, Fiers W, Herman AG. Inflammatory properties of recombinant tumor necrosis factor in rabbit skin in vivo. J Exp Med 1989;169:2227-32.
8. Esparza I, Mannel D, Ruppel A, Falk W, Krammer PH. Interferon gamma and lymphotoxin or tumor necrosis factor act synergistically to induce macrophage killing of tumor cells and schistosoma of Schistosoma mansoni. J Exp Med 1987;166:589-94.
9. Nakane A, Minagawa T, Kato K. Endogenous tumor necrosis factor (cachectin) is essential to host resistance against Listeria monocytogenes infection. Infect Immun 1988;56:2563-9.
10. Cross AS, Sadoff JC, Kelly N, Bernton E, Gemski P. Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine interleukin 1 alpha protects mice from lethal bacterial infection. J Exp Med 1989;169:2021-9.
11. Titus RG, Sherry B, Cerami A. Tumor necrosis factor plays a protective role in experimental murine cutaneous leishmaniasis. J Exp Med 1989;6:2097-104.
12. Liew FY, Parkinson C, Millott S, Severn A, Carrier M. Tumor necrosis factor (TNF alpha) in leishmaniasis. I. TNF alpha mediates host protection against cutaneous leishmaniasis. Immunobiology 1990;69: 570-3.
13. Beutler B, Milsark W, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985;229:869-71.
14. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986;234:470-4.
15. Grau GE, Fajardo LF, Piguet PF, Allet B, Lambert PH, Vassalli P. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science 1987;237:1210-2.
16. Chulay JD, Bryceson AD. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 1983;32:475-9.
17. Badaro R, Jones TC, Carvalho EM, et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis 1986;154:1003-11.
18. Badaro R, Falcoff E, Badaro FS, et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med 1990;322:16-21.
19. Carvalho EM, Bacellar O, Reed SG, Barral A, Rocha H. Visceral leishmaniasis: a disease associated with inability of lymphocyte to activate macrophage to kill leishmania. Braz J Med Biol Res 1988;21: 85-92.
20. Murray HW, Berman JD, Wright SD. Immunochemotherapy for intracellular Leishmania donovani infection: γ interferon plus pentavalent antimony. J Infect Dis 1988;157:973-8.
21. Galvão-Castro B, Sa Ferreira JA, Marzochi KF, Coutinho SG, Lambert PH. Polyclonal B-cell activation, circulating immune complexes and auto-immunity in human visceral leishmaniasis. Clin Exp Immunol 1984;56:58-66.
22. Bohme MWJ, Evans DA, Miles MA, Holborow EJ. Occurrence of autoantibodies to intermediate filament in human visceral leishmaniasis and their induction by experimental polyclonal B-cell activation. Immunology 1986;59:583-8.
23. Oliff A, Defeo-Jones D, Boyer M, et al. Tumors secreting human TNF/cachectin induce cachexia in mice. Cell 1987;50:555-60.
24. Wei H, Tracey KJ, Monogue KR, et al. Cachectin mediates suppressed food intake and anemia during chronic administration. FASEB J 1987;46:1338-42.
25. Tracey KJ, Wei H, Monogue KR, et al. Cachectin/tumor necrosis factor induces cachexia, anemia and inflammation. J Exp Med 1988;167: 1211-27.
26. Beutler B, Mahoney J, Le Trang N, Pekala P, Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW264.7. J Exp Med 1985;161:984-9.
27. Torti FM, Dieckmann B, Beutler B, Cerami A, Ringold GM. A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia. Science 1985;229:867-9.
28. Brouckaert P, Springs DR, Demetri G, Kufe DW, Fiers W. Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma. J Exp Med 1989;169:2257-62.
29. Scuderi P, Lam KS, Ryan KJ, et al. Raised serum levels of tumor necrosis factor in parasitic infections. Lancet 1986;2:1364-5.
30. Teppo AM, Maury CPJ. Radio immunoassay of tumor necrosis factor in serum. Clin Chem 1987;33:2024-7.
31. Kern P, Hemmer CJ, Van-Damme J, Gruss HJ, Dietrich M. Elevated tumor necrosis factor alpha and interleukin-6 serum levels as markers for complicated Plasmodium falciparum malaria. Am J Med 1989;87:139-43.
32. Grau GE, Taylor TE, Molyneux ME, et al. Tumor necrosis factor and disease severity in children with falciparum malaria. N Engl J Med 1989;320:1586-91.
33. Bate CA, Taverne J, Playfair JH. Malarial parasites induce TNF production by macrophages. Immunology 1988;64:227-31.
34. Picot S, Peyron F, Vuillez JP, Barbe G, Marsh K, Ambroise-Thomas P. Tumor necrosis factor production by human macrophages stimulated in vitro by Plasmodium falciparum. Infect Immun 1990;58:214-6.
35. Bate CAW, Taverne J, Playfair JHL. Soluble malarial antigens are toxic and induce the production of tumour necrosis factor in vivo. Immunology 1989;66:600-5.
36. Lin Y, Collins JL, Case PG, Patek PQ. Effect of mycoplasmas on natural cytotoxic activity and release of tumor necrosis factor alpha by spleen cells. Infect Immun 1988;56:3072-5.
37. Valone SE, Rich EA, Wallis RS, Ellner JJ. Expression of tumor necrosis factor in vitro by human mononuclear phagocytes stimulated with whole Mycobacterium bovis BCG and mycobactenal antigens. Infect Immun 1988;56:3313-5.
38. Nedwin GE, Sredersky LP, Bringman TS, Palladino MA, Goeddel DV. Effect of interleukin 2, interferon gamma, and mitogen on the production of tumor necrosis factors alpha and beta. J Immunol 1985;135: 2492-7.
39. Fiers W, Brouckaert P, Devos R, et al. Molecular and cellular biology of tumor necrosis factor, interferon gamma, and their synergism. In: Cantell K, Schellekens H, eds. The biology of the interferon system. Amsterdam: Martinus Nijhoff, 1986.
40. Drapier JC, Wietzerbin J, Hibbs JB Jr. Interferon gamma and tumor necrosis factor induce the arginine-dependent cytotoxic effector mechanism in murine macrophages. Eur J Immunol 1988, 18:1587-92.
41. Carvalho EM, Teixeira RS, Johnson WD. Cell mediated immunity in American visceral leishmaniasis. Reversible immunosuppression during acute infection. Infect Immun 1981;22:649-54.